Xuesong Han1, Ahmedin Jemal2. 1. Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia. Electronic address: xuesong.han@cancer.org. 2. Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.
Abstract
INTRODUCTION: Mutations in BRCA genes are strongly associated with increased risk of breast and ovarian cancer, and it is recommended that women at high risk for these mutations be referred for genetic counseling and testing. The Affordable Care Act (ACA) provision implemented in 2010 eliminated cost sharing for BRCA genetic testing for privately insured women with family history of BRCA-related cancers. METHODS: Using a nationally representative sample from the National Health Interview Survey, this study examined trends in genetic testing for breast and ovarian cancer risk from 2005 to 2015 among women by family history and insurance status. To assess the impact of the ACA provision, a difference-in-differences strategy was used to compare changes in genetic testing after ACA implementation between women with a family history of breast or ovarian cancer and those with a family history of other cancers, stratified by insurance type. Analyses were conducted in 2016. RESULTS: Genetic testing for breast and ovarian cancer risk increased among women with private or public insurance, but not among uninsured women. Among privately insured women, those with family history of breast or ovarian cancer experienced a net increase of 2.9 percentage points (p=0.001) over those with a family history of other cancers, but no significant difference was observed among women with public insurance, suggesting a positive effect of the ACA provision. CONCLUSIONS: This study underscores the continued need to improve access to care for all populations. Future work should monitor the impact of policy on genetic testing among the high-risk population.
INTRODUCTION: Mutations in BRCA genes are strongly associated with increased risk of breast and ovarian cancer, and it is recommended that women at high risk for these mutations be referred for genetic counseling and testing. The Affordable Care Act (ACA) provision implemented in 2010 eliminated cost sharing for BRCA genetic testing for privately insured women with family history of BRCA-related cancers. METHODS: Using a nationally representative sample from the National Health Interview Survey, this study examined trends in genetic testing for breast and ovarian cancer risk from 2005 to 2015 among women by family history and insurance status. To assess the impact of the ACA provision, a difference-in-differences strategy was used to compare changes in genetic testing after ACA implementation between women with a family history of breast or ovarian cancer and those with a family history of other cancers, stratified by insurance type. Analyses were conducted in 2016. RESULTS: Genetic testing for breast and ovarian cancer risk increased among women with private or public insurance, but not among uninsured women. Among privately insured women, those with family history of breast or ovarian cancer experienced a net increase of 2.9 percentage points (p=0.001) over those with a family history of other cancers, but no significant difference was observed among women with public insurance, suggesting a positive effect of the ACA provision. CONCLUSIONS: This study underscores the continued need to improve access to care for all populations. Future work should monitor the impact of policy on genetic testing among the high-risk population.
Authors: Stacy W Gray; Rebecca A Ottesen; Madeline Currey; Mihaela Cristea; Janet Nikowitz; Susan Shehayeb; Vanessa Lozano; Julie Hom; Julie Kilburn; Lisa N Lopez; Sam Wing; Ernesto Sosa; Jenny Shen; Michael Morris; Bedros Dilsizian; Thomas Joseph; James Shen; Camille Adeimy; Tanyanika Phillips; Bahareh Bahadini; Joyce C Niland Journal: JCO Clin Cancer Inform Date: 2022-09
Authors: Mahip Acharya; Kristin K Zorn; Melinda E Simonson; Milan Bimali; Gary W Moore; Cheng Peng; Bradley C Martin Journal: Hered Cancer Clin Pract Date: 2022-05-23 Impact factor: 2.164
Authors: Lydia E Pace; Nadine Tung; Yeonsoo S Lee; Jada G Hamilton; Camila Gabriel; Anna Revette; Sahitya Raja; Colby Jenkins; Anthony Braswell; Kelly Morgan; Jeffrey Levin; Jeremy Block; Susan M Domchek; Katherine Nathanson; Heather Symecko; Kelsey Spielman; Beth Karlan; Daniella Kamara; Jenny Lester; Kenneth Offit; Judy E Garber; Nancy L Keating Journal: J Gen Intern Med Date: 2021-06-25 Impact factor: 6.473
Authors: Ridgely Fisk Green; Mary Ari; Katherine Kolor; W David Dotson; Scott Bowen; Nancy Habarta; Juan L Rodriguez; Lisa C Richardson; Muin J Khoury Journal: Genet Med Date: 2018-06-15 Impact factor: 8.822